介入性心臟病学及週边血管器材市场：成长机会、成长要素、产业趋势分析及2026-2035年预测

全球介入性心臟病学和周边血管器械市场预计到 2025 年将达到 277 亿美元，年复合成长率为 8.2%，到 2035 年将达到 608 亿美元。

全球血管疾病盛行率上升、週边血管器械技术的持续创新、微创手术的日益普及以及政府为应对心血管疾病负担而增加的医疗费用支出，共同推动了这一增长。这些医疗设备，例如支架、球囊和导管，使医疗专业人员能够在无需进行大型手术的情况下治疗心臟和血管疾病。微创治疗在现代心血管医学中备受青睐，因为它们可以缩短患者復原时间、降低手术相关风险并改善临床疗效。公共卫生政策和报销政策进一步促进了微创治疗的普及，使先进的医疗设备更容易取得且更具成本效益。创新的器械设计、监管支援以及患者对更安全手术的需求，持续推动全球市场的扩张。

预计到2025年，支架市场规模将达到104亿美元。支架是一种小型、可扩张的网状管，能够恢復狭窄或阻塞动脉的血流，广泛应用于冠状动脉和周边血管介入治疗。其临床疗效、可靠性和持续的设计改进使其成为微创治疗的理想选择。与传统手术相比，药物释放型支架透过降低血管再阻塞和再次治疗率并缩短恢復时间，进一步巩固了其市场主导地位。

预计到2025年，血管成形术市场规模将达到142亿美元，并在2026年至2035年间以8.3%的复合年增长率成长。血管成形术是一种将球囊扩张到动脉内以疏通阻塞血管的手术，通常随后会植入支架。此手术广泛用于治疗冠状动脉疾病和周边动脉疾病，可减少开胸手术的需求并加速患者復原。由于其微创性和治疗心血管疾病的有效性，血管成形术是全球最常进行的手术之一。

预计到2025年，北美介入性心臟病学和周边血管器械市场将占据28%的市场份额。该地区的主导地位得益于心血管疾病的高发病率、先进的医疗基础设施、有利的报销政策以及微创技术的早期应用。人们对心血管疾病管理的日益重视、技术的进步以及患者对微创手术的偏好，都将继续巩固北美市场的主导地位。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 全球血管疾病盛行率不断上升
    • 週边血管装置的技术进步
    • 微创手术的广泛应用
    • 政府支出增加与心血管疾病负担有关
  • 产业潜在风险与挑战：
    • 严格的法规结构
    • 与医疗设备相关的术后併发症
  • 市场机会
    • 门诊及门诊手术中心扩建
    • 扩大机器人技术在介入手术的应用
• 成长潜力分析
• 监理情势
• 技术进步（基于初步调查）
  • 当前技术趋势
  • 新兴技术
• 未来市场趋势（基于初步研究）
• 还款方案（基于初步调查）
• 波特的分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估价与预测：依产品划分，2022-2035年

• 介入导管
• 导管导引线
• 支架
  • 生物可吸收支架
  • 药物释放型支架
  • 裸金属支架
  • 其他支架
• PTCA球囊扩张术
• 动脉粥状硬化斑块切除术装置
• 慢性完全闭塞装置
• 人工外科移植
• 栓塞预防装置
• 下腔静脉滤器
• 其他产品

第六章 市场估计与预测：依应用领域划分，2022-2035年

• 先天性心臟疾病矫正
• 冠状动脉血栓切除术
• 血管成形术
• 瓣环成形手术
• 经皮瓣修復
• 其他用途

第七章 市场估计与预测：依最终用途划分，2022-2035年

• 医院
• 门诊手术中心
• 其他最终用户

第八章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 沙乌地阿拉伯
  • 南非
  • 阿拉伯聯合大公国

第九章：公司简介

• Abbott Laboratories
• AngioDynamics
• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Biotronik SE &Co. KG
• Boston Scientific Corporation
• Cardinal Health
• Cook Medical
• Cordis
• Endologix
• iVascular
• Medtronic Plc
• Teleflex Inc.
• Terumo Corporation
• WL Gore &Associates, Inc.

The Global Interventional Cardiology and Peripheral Vascular Devices Market was valued at USD 27.7 billion in 2025 and is estimated to grow at a CAGR of 8.2% to reach USD 60.8 billion by 2035.

This growth is fueled by the rising prevalence of vascular diseases worldwide, continuous technological innovations in peripheral vascular devices, increasing adoption of minimally invasive procedures, and growing government healthcare spending to address cardiovascular disease burdens. These devices, including stents, balloons, and catheters, enable healthcare professionals to treat heart and blood vessel conditions without major surgery. Minimally invasive interventions reduce patient recovery time, lower procedural risks, and improve clinical outcomes, making them highly desirable in modern cardiovascular care. Public health initiatives and reimbursement policies further support widespread adoption, making advanced devices more accessible and cost-effective. The combination of innovative device design, regulatory support, and patient preference for safer procedures continues to drive market expansion globally.

The stents segment generated USD 10.4 billion in 2025. Stents, small expandable mesh tubes, restore blood flow in narrowed or blocked arteries and are used in both coronary and peripheral interventions. Their clinical effectiveness, reliability, and continuous design improvements make them the preferred solution for minimally invasive treatments. Drug-eluting stents reduce restenosis and repeat procedures while shortening recovery time compared to traditional surgery, reinforcing their market dominance.

The angioplasty segment reached USD 14.2 billion in 2025 and is expected to grow at a CAGR of 8.3% during 2026-2035. Angioplasty involves inflating a balloon inside an artery to open blocked vessels, often followed by stent placement. It is widely performed for coronary and peripheral artery disease, reducing the need for open-heart surgery and promoting faster patient recovery. Its minimally invasive nature and effectiveness in treating cardiovascular conditions make angioplasty one of the most performed procedures worldwide.

North America Interventional Cardiology and Peripheral Vascular Devices Market held a 28% share in 2025. The region's market leadership is supported by a high prevalence of cardiovascular conditions, advanced healthcare infrastructure, favorable reimbursement policies, and the early adoption of minimally invasive technologies. Increasing awareness of cardiovascular disease management, technological advancements, and patient preference for less invasive procedures continue to strengthen North America's dominant market position.

Key players in the Global Interventional Cardiology and Peripheral Vascular Devices Market include Abbott Laboratories, AngioDynamics, B. Braun Melsungen AG, Becton, Dickinson and Company, Biotronik SE & Co. KG, Boston Scientific Corporation, Cardinal Health, Cook Medical, Cordis, Endologix, iVascular, Medtronic Plc, Teleflex Inc., Terumo Corporation, and W.L. Gore & Associates, Inc. Companies in the Interventional Cardiology and Peripheral Vascular Devices Market strengthen their position by investing heavily in R&D to enhance device performance, safety, and design. Strategic collaborations with hospitals, research institutions, and technology partners enable the development of next-generation stents, balloons, and catheters. Firms focus on expanding global distribution networks, securing regulatory approvals in new regions, and offering training programs for healthcare providers to increase adoption. Marketing efforts highlight clinical efficacy and procedural benefits to reinforce trust among physicians and patients.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product trends
  • 2.2.3 Application trends
  • 2.2.4 End use trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing prevalence of vascular diseases worldwide
    • 3.2.1.2 Technological advancements in peripheral vascular devices
    • 3.2.1.3 Rising adoption of minimally invasive procedures
    • 3.2.1.4 Increasing government spending pertaining to cardiovascular diseases burden
  • 3.2.2 Industry Pitfalls and Challenges:
    • 3.2.2.1 Stringent regulatory framework
    • 3.2.2.2 Post-procedural complications associated with devices
  • 3.2.3 Market Opportunities
    • 3.2.3.1 Growth in outpatient and ambulatory surgical centers
    • 3.2.3.2 Increasing use of robotics in interventions
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological advancements (Driven by Primary Research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by Primary Research)
• 3.7 Reimbursement scenario (Driven by Primary Research)
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Interventional catheters
• 5.3 Guidewires
• 5.4 Stents
  • 5.4.1 Bioabsorbable stents
  • 5.4.2 Drug eluting stents
  • 5.4.3 Bare metal stents
  • 5.4.4 Other stents
• 5.5 PTCA balloons
• 5.6 Atherectomy devices
• 5.7 Chronic total occlusion devices
• 5.8 Synthetic surgical grafts
• 5.9 Embolic protection devices
• 5.10 Inferior vena cava filters
• 5.11 Other products

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Congenital heart defect correction
• 6.3 Coronary thrombectomy
• 6.4 Angioplasty
• 6.5 Valvuloplasty
• 6.6 Percutaneous valve repair
• 6.7 Other applications

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals
• 7.3 Ambulatory surgical centers
• 7.4 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 South Africa
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 AngioDynamics
• 9.3 B. Braun Melsungen AG
• 9.4 Becton, Dickinson and Company
• 9.5 Biotronik SE & Co. KG
• 9.6 Boston Scientific Corporation
• 9.7 Cardinal Health
• 9.8 Cook Medical
• 9.9 Cordis
• 9.10 Endologix
• 9.11 iVascular
• 9.12 Medtronic Plc
• 9.13 Teleflex Inc.
• 9.14 Terumo Corporation
• 9.15 W.L. Gore & Associates, Inc.